PET-MRI Esophagus Feasibility Study

NCT05796102 | Recruiting

• 1 other identifier: 22-5780
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single arm, single centre, investigator initiated study to investigate the feasibility of using PET-MRI imaging in radiation treatment workflow in up to 15 patients with esophagogastric cancer. PET-MRI imaging will be completed before the start of radiation treatment. MRI imaging will be completed during radiation treatment and after radiation treatment. These images will not be used to plan the radiation treatment and routine clinical care will be provided. The goal of this study is to gather information that will allow the radiation team to include MRI and PET imaging into the radiation treatment workflow for patients with esophageal cancer receiving radiation therapy in the future.

Conditions

Esophagogastric Cancer

Outcome Measures

Primary Outcomes (1)

• Feasibility of PET-MRI to visualize and assess impact of RT treatments on esophagogastric tumors

  Detection of metastases on DWI and gadolinium enhanced T1-weighted 3D VIBE sequences.

  2 years

Secondary Outcomes (2)

• Difference in manual GTV segmentation using PET-MRI

  2 years

• Quantification of dosimetric advantages of PET-MRI treatment plan

  2 years

Study Arms (1)

PET-MRI

EXPERIMENTAL

PET-MRI in esophagogastric cancers

Procedure: PET-MRI

Interventions

PET-MRI PROCEDURE

A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position. Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment

PET-MRI

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients 18 years or older
• Diagnosed with locally advanced esophageal cancer being considered for conventional RT \>4 weeks
• Ability and willingness to provide written informed consent

You may not qualify if:

• Contraindication for MRI
• Contraindication for Gadolinium (i.e. inability to lie supine for at least 60 minutes)
• Any patient who is pregnant or breastfeeding
• Pacemaker or implanted defibrillator
• Claustrophobia

Sponsors & Collaborators

• University Health Network, Toronto: lead

Study Sites (1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

RECRUITING

Central Study Contacts

Rebecca K S Wong, MD

CONTACT

4169462000; rebecca.wong@uhn.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 9, 2022
• First Posted: April 3, 2023
• Study Start: March 28, 2023
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2027
• Last Updated: March 5, 2026

Record last verified: 2026-03

Locations

CA (1)